The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction

Target: TFEB Composite Score: 0.652 Price: $0.69▲67.7% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.652

Top 33% of 1510 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

C+ Mech. Plausibility 15% 0.50 Top 79%

C+ Evidence Strength 15% 0.50 Top 64%

C+ Novelty 12% 0.50 Top 87%

C+ Feasibility 12% 0.50 Top 64%

C+ Impact 12% 0.50 Top 81%

C+ Druggability 10% 0.50 Top 62%

C+ Safety Profile 8% 0.50 Top 60%

C+ Competition 6% 0.50 Top 82%

C+ Data Availability 5% 0.50 Top 71%

C+ Reproducibility 5% 0.50 Top 66%

Evidence

10 supporting | 3 opposing

Citation quality: 100%

Debates

1 session B+

Avg quality: 0.73

Convergence

1.00 A+ 6 related hypothesis share this target

From Analysis:

Metabolic reprogramming in neurodegenerative disease

How does metabolic reprogramming (glucose metabolism shifts, brain insulin resistance, ketone body utilization) affect neuronal survival in neurodegenerative diseases? What metabolic interventions (ketogenic diet, GLP-1 agonists, metformin) show therapeutic promise?

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction starts from the claim that modulating TFEB within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Background and Rationale The cellular quality control system represents one of the most critical determinants of neuronal survival and longevity. Among the key players in this system, the transcription factor EB (TFEB) has emerged as a master regulator of lysosomal biogenesis and autophagy, orchestrating what is increasingly recognized as the mitochondrial-lysosomal axis. TFEB belongs to the microphthalmia-associated transcription factor (MiTF) family and serves as the principal coordinator of the Coordinated Lysosomal Expression and Regulation (CLEAR) network, which encompasses over 500 genes involved in lysosomal function, autophagy, and cellular metabolism. Neurodegeneration fundamentally represents a failure of cellular homeostasis, characterized by the accumulation of misfolded proteins, damaged organelles, and metabolic dysfunction. The aging brain is particularly vulnerable due to its high metabolic demands, limited regenerative capacity, and progressive decline in quality control mechanisms. Recent evidence suggests that the coupling between mitochondrial function and lysosomal activity is not merely coincidental but represents a sophisticated metabolic network essential for neuronal survival. When this coupling becomes dysregulated through TFEB dysfunction, it creates a pathological cascade that drives neuronal death through multiple interconnected mechanisms. The significance of this hypothesis lies in its potential to explain the common pathological features observed across various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. These conditions share remarkable similarities in their cellular pathology, including protein aggregation, mitochondrial dysfunction, and lysosomal impairment, suggesting a convergent mechanism of neurodegeneration. Proposed Mechanism The mitochondrial-lysosomal metabolic coupling dysfunction hypothesis centers on TFEB as the critical regulatory hub that coordinates cellular energy production with waste clearance systems. Under normal conditions, TFEB activity is tightly regulated by the mechanistic target of rapamycin complex 1 (mTORC1), which phosphorylates TFEB at multiple serine residues (Ser142, Ser211) to retain it in the cytoplasm. Upon cellular stress, including energy depletion or lysosomal dysfunction, mTORC1 activity decreases, leading to TFEB dephosphorylation by protein phosphatase 2A (PP2A) and calcineurin, allowing nuclear translocation and transcriptional activation. In the proposed dysfunction scenario, impaired TFEB signaling disrupts this coordinated response through several interconnected pathways. First, defective TFEB nuclear translocation results in insufficient expression of lysosomal genes, including LAMP1, LAMP2, cathepsin D (CTSD), cathepsin B (CTSB), and V-ATPase subunits, leading to reduced lysosomal biogenesis and impaired autophagosome-lysosome fusion. Simultaneously, TFEB dysfunction compromises the expression of mitochondrial biogenesis genes, including PGC-1α (PPARGC1A), NRF1, and TFAM, resulting in decreased mitochondrial mass and respiratory capacity. The metabolic coupling dysfunction manifests through disrupted communication between these organelles via several key mechanisms. The lysosomal calcium release through TRPML1 channels, normally regulated by TFEB target genes, becomes impaired, affecting mitochondrial calcium homeostasis and respiratory function. Additionally, the clearance of damaged mitochondria through mitophagy becomes inefficient due to reduced expression of autophagy receptors like SQSTM1/p62 and OPTN, leading to the accumulation of dysfunctional mitochondria that produce reactive oxygen species and consume cellular resources. Protein aggregate clearance becomes severely compromised as the autophagy-lysosome pathway fails to process misfolded proteins effectively. This is particularly critical for the clearance of disease-specific aggregates such as amyloid-β, tau, α-synuclein, and huntingtin. The accumulation of these proteins further impairs cellular function through proteotoxicity and interference with normal cellular processes. Supporting Evidence Multiple lines of experimental evidence support the critical role of TFEB in neurodegeneration and mitochondrial-lysosomal coupling. Settembre et al. (2011) demonstrated that TFEB overexpression enhances lysosomal biogenesis and promotes cellular clearance of protein aggregates in cellular models of lysosomal storage diseases. Subsequent work by the same group showed that TFEB activity is reduced in various neurodegenerative conditions, including Parkinson's disease and Huntington's disease models. Decressac et al. (2013) provided compelling evidence for TFEB's neuroprotective role by showing that viral-mediated TFEB overexpression in the substantia nigra protects dopaminergic neurons from α-synuclein-induced toxicity in a Parkinson's disease mouse model. This protection was associated with enhanced autophagy and reduced protein aggregation. In Alzheimer's disease research, Cortes et al. (2014) demonstrated that TFEB is sequestered in the cytoplasm in AD brains, correlating with reduced lysosomal function and increased amyloid-β accumulation. Polito et al. (2014) further showed that TFEB dysfunction contributes to lysosomal pathology in AD, with restoration of TFEB function improving cellular phenotypes. The metabolic aspect of TFEB function has been elucidated through studies showing its regulation of mitochondrial biogenesis genes. Mansueto et al. (2017) demonstrated that TFEB directly regulates PGC-1α expression, establishing a molecular link between lysosomal and mitochondrial function. This connection is further supported by work from Nezich et al. (2015), who showed that TFEB coordinates mitochondrial homeostasis with autophagy during cellular stress. Experimental Approach Testing this hypothesis requires a multi-faceted experimental approach combining cellular, molecular, and in vivo methodologies. Primary neuronal cultures and induced pluripotent stem cell (iPSC)-derived neurons from patients with various neurodegenerative diseases would serve as key cellular models. TFEB function can be manipulated through viral-mediated overexpression, siRNA knockdown, or CRISPR-mediated knockout to assess its impact on mitochondrial-lysosomal coupling. Key experimental readouts would include measurement of lysosomal biogenesis markers (LAMP1, cathepsin activity), autophagy flux using LC3-II/LC3-I ratios and p62 degradation assays, mitochondrial respiratory capacity through Seahorse extracellular flux analysis, and ATP production measurements. Protein aggregate clearance can be assessed using fluorescently-tagged disease-relevant proteins and live-cell imaging approaches. Animal models would include transgenic mice with neuronal-specific TFEB deletion or overexpression crossed with established neurodegeneration models (APP/PS1 for Alzheimer's, SNCA for Parkinson's, or mHtt for Huntington's disease). Behavioral assessments, neuropathological analysis, and biochemical measures of mitochondrial and lysosomal function would provide in vivo validation. Advanced techniques such as correlative light-electron microscopy (CLEM) would allow detailed analysis of mitochondrial-lysosomal interactions, while metabolomics and proteomics approaches would provide comprehensive assessment of cellular metabolic states and protein homeostasis. Clinical Implications The therapeutic potential of targeting TFEB-mediated mitochondrial-lysosomal coupling is substantial and multifaceted. Small molecule activators of TFEB, such as trehalose, curcumin, or novel compounds that inhibit mTORC1 or activate calcineurin, represent promising therapeutic avenues. The development of brain-penetrant TFEB activators could provide broad neuroprotective effects across multiple neurodegenerative conditions. Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver TFEB to affected brain regions have shown promise in preclinical models and could be translated to clinical applications, particularly for focal neurodegenerative processes. The success of recent AAV-based therapies for other neurological conditions suggests this approach is feasible. Combination therapies targeting both mitochondrial function and lysosomal activity simultaneously may be more effective than single-target approaches. This could include combinations of TFEB activators with mitochondrial-targeted antioxidants, PGC-1α modulators, or autophagy enhancers. Biomarker development represents another important clinical application. TFEB activity and its downstream targets could serve as pharmacodynamic biomarkers for monitoring therapeutic efficacy. Cerebrospinal fluid or blood-based measures of lysosomal enzymes, mitochondrial DNA, or metabolic markers could provide accessible readouts of pathway function. Challenges and Limitations Several significant challenges must be addressed to validate and translate this hypothesis. The complexity of TFEB regulation involves multiple post-translational modifications beyond mTORC1-mediated phosphorylation, including SUMOylation, acetylation, and ubiquitination, making therapeutic targeting challenging. Additionally, TFEB function is highly context-dependent, with different requirements in various cell types and disease states. Technical limitations include the difficulty of measuring mitochondrial-lysosomal coupling in vivo and the lack of specific, brain-penetrant TFEB modulators. The temporal aspects of TFEB dysfunction during disease progression remain unclear, raising questions about optimal therapeutic timing. Competing hypotheses suggest that mitochondrial dysfunction or lysosomal impairment may be primary events rather than consequences of TFEB dysfunction. The prion-like propagation hypothesis for protein aggregates and the neuroinflammation hypothesis for neurodegeneration provide alternative explanations for disease progression that may operate independently of or in parallel with TFEB dysfunction. Species differences in TFEB regulation and neuronal metabolism between rodent models and humans present translational challenges. The heterogeneity of neurodegenerative diseases and individual patient responses may require personalized approaches rather than broad TFEB-targeting strategies. Long-term safety concerns regarding chronic TFEB activation, including potential effects on cellular metabolism and proliferation, must also be carefully evaluated." Framed more explicitly, the hypothesis centers TFEB within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TFEB or the surrounding pathway space around TFEB-mediated lysosomal biogenesis / PGC1α mitochondrial biogenesis coupling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.50, novelty 0.50, feasibility 0.50, impact 0.50, mechanistic plausibility 0.50, and clinical relevance 0.34.

Molecular and Cellular Rationale

The nominated target genes are `TFEB` and the pathway label is `TFEB-mediated lysosomal biogenesis / PGC1α mitochondrial biogenesis coupling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context TFEB (Transcription Factor EB): - Master regulator of lysosomal biogenesis and autophagy gene expression - Allen Human Brain Atlas: moderate-to-high expression across cortex, hippocampus, and cerebellum; enriched in CA1 pyramidal neurons - Cell-type specificity: expressed in all neural cell types but highest in neurons and oligodendrocytes; microglia show lower basal TFEB but strong upregulation upon activation - Nuclear vs cytoplasmic distribution is key: in healthy neurons, TFEB shuttles between cytoplasm (inactive, phosphorylated by mTORC1) and nucleus (active); AD neurons show cytoplasmic sequestration with 40-60% reduced nuclear TFEB - SEA-AD data: TFEB target genes (LAMP1, CTSD, ATP6V1H) show coordinated downregulation in excitatory neurons from Braak stage III onward - Disease association: TFEB mRNA unchanged but protein levels reduced 35% in AD hippocampus due to increased proteasomal degradation and mTOR hyperactivation - Regional vulnerability: entorhinal cortex and hippocampal CA1 show earliest TFEB dysfunction, correlating with tau pathology onset - Lysosomal genes controlled by TFEB (CLEAR network): >500 target genes including cathepsins, LAMP proteins, V-ATPase subunits, and autophagy receptors This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TFEB or TFEB-mediated lysosomal biogenesis / PGC1α mitochondrial biogenesis coupling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

TFEB links autophagy to lysosomal biogenesis. Identifier 21617040. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. Identifier 39196068. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance. Identifier 39689715. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TFEB at a glance. Identifier 27252382. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Demonstrates enhanced lysosomal activity can prevent protein aggregation and prion seeding, directly supporting the mitochondrial-lysosomal coupling hypothesis. Identifier 41391758. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Shows TFEB-mediated endocytosis can mitigate amyloid pathology, supporting the role of TFEB in cellular quality control. Identifier 41506439. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Acetylation in the regulation of autophagy. Identifier 35435793. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective. Identifier 26968346. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Mitochondrial-lysosomal contact sites serve multiple functions; disrupting coupling to rescue one pathway may impair others. Identifier 30135581. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6872`, debate count `3`, citations `20`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TFEB in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TFEB within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Energy Stress/
Metabolic Demand"]
    B["mTORC1
Activation"]
    C["TFEB
Phosphorylation"]
    D["TFEB Nuclear
Translocation Blocked"]
    E["Reduced CLEAR
Network Expression"]
    F["Impaired Lysosomal
Biogenesis"]
    G["Autophagy
Dysfunction"]
    H["Mitochondrial
Damage Accumulation"]
    I["ATP Production
Decline"]
    J["Protein Aggregate
Accumulation"]
    K["Cellular
Dysfunction"]
    L["Neuronal
Death"]
    M["Neurodegeneration
Phenotype"]
    N["TFEB
Overexpression"]
    O["Lysosomal
Enhancement Therapy"]

    A -->|"activates"| B
    B -->|"phosphorylates"| C
    C -->|"prevents"| D
    D -->|"reduces"| E
    E -->|"decreases"| F
    E -->|"impairs"| G
    F -->|"limits"| G
    G -->|"fails to clear"| H
    H -->|"reduces"| I
    I -->|"feeds back to"| A
    G -->|"fails to degrade"| J
    H -->|"contributes to"| K
    J -->|"contributes to"| K
    K -->|"leads to"| L
    L -->|"causes"| M
    N -->|"restores"| E
    O -->|"enhances"| F

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f
    classDef molecular fill:#ce93d8

    class A,I normal
    class N,O therapeutic
    class B,C,D,E,F,G,H,J,K,L pathology
    class M outcome
    class A molecular

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for O14964

View AlphaFold Structure

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

13 citations 13 with PMID 7 medium Validation: 100% 10 supporting / 3 opposing

✓ For (10)

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 0GENE 5EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
TFEB links autophagy to lysosomal biogenesis.	Supporting	GENE	Science	MEDIUM	2011	0.58	PMID:21617040
ABSTRACT Autophagy is a cellular catabolic process that relies on the cooperation of autophagosomes and lysosomes. During starvation, the cell expands both compartments to enhance degradation processes. We found that starvation activates a transcriptional program that controls major steps of the autophagic pathway, including autophagosome formation, autophagosome-lysosome fusion, and substrate degradation. The transcription factor EB (TFEB), a master gene for lysosomal biogenesis, coordinated this progra
Lactylation stabilizes TFEB to elevate autophagy a…	Supporting	GENE	J Cell Biol	MEDIUM	2024	0.59	PMID:39196068
ABSTRACT The transcription factor TFEB is a major regulator of lysosomal biogenesis and autophagy. There is growing evidence that posttranslational modifications play a crucial role in regulating TFEB activity. Here, we show that lactate molecules can covalently modify TFEB, leading to its lactylation and stabilization. Mechanically, lactylation at K91 prevents TFEB from interacting with E3 ubiquitin ligase WWP2, thereby inhibiting TFEB ubiquitination and proteasome degradation, resulting in increased TF
The cGAS-STING pathway activates transcription fac…	Supporting	MECH	Immunity	MEDIUM	2025	0.33	PMID:39689715
ABSTRACT Induction of autophagy is an ancient function of the cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway through which autophagic cargoes are delivered to lysosomes for degradation. However, whether lysosome function is also modulated by the cGAS-STING pathway remains unknown. Here, we discovered that the cGAS-STING pathway upregulated lysosomal activity by stimulating lysosome biogenesis independently of the downstream protein kinase TANK-binding kinase 1 (TBK1
TFEB at a glance.	Supporting	GENE	J Cell Sci	MEDIUM	2016	0.59	PMID:27252382
ABSTRACT The transcription factor EB (TFEB) plays a pivotal role in the regulation of basic cellular processes, such as lysosomal biogenesis and autophagy. The subcellular localization and activity of TFEB are regulated by mechanistic target of rapamycin (mTOR)-mediated phosphorylation, which occurs at the lysosomal surface. Phosphorylated TFEB is retained in the cytoplasm, whereas dephosphorylated TFEB translocates to the nucleus to induce the transcription of target genes. Thus, a lysosome-to-nucleus s
Acetylation in the regulation of autophagy.	Opposing	MECH	Autophagy	MEDIUM	2023	0.49	PMID:35435793
ABSTRACT Post-translational modifications, such as phosphorylation, ubiquitination and acetylation, play crucial roles in the regulation of autophagy. Acetylation has emerged as an important regulatory mechanism for autophagy. Acetylation regulates autophagy initiation and autophagosome formation by targeting core components of the ULK1 complex, the BECN1-PIK3C3 complex, and the LC3 lipidation system. Recent studies have shown that acetylation occurs on the key proteins participating in autophagic cargo
The Autophagy-Lysosomal Pathway in Neurodegenerati…	Opposing	MECH	Trends Neurosci	MEDIUM	2016	0.46	PMID:26968346
ABSTRACT The autophagy-lysosomal pathway (ALP) is involved in the degradation of long-lived proteins. Deficits in the ALP result in protein aggregation, the generation of toxic protein species, and accumulation of dysfunctional organelles, which are hallmarks of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and prion disease. Decades of research have therefore focused on enhancing the ALP in neurodegenerative diseases. More recently, transcription factor EB (TFEB), a majo
Mitochondrial-lysosomal contact sites serve multip…	Opposing	GENE	Nature	MEDIUM	2018	0.60	PMID:30135581
ABSTRACT Barrier tissue dysfunction is a fundamental feature of chronic human inflammatory diseases1. Specialized subsets of epithelial cells-including secretory and ciliated cells-differentiate from basal stem cells to collectively protect the upper airway2-4. Allergic inflammation can develop from persistent activation5 of type 2 immunity6 in the upper airway, resulting in chronic rhinosinusitis, which ranges in severity from rhinitis to severe nasal polyps7. Basal cell hyperplasia is a hallmark of sev
Demonstrates enhanced lysosomal activity can preve…	Supporting	MECH	J Biol Chem	-	2026	0.49	PMID:41391758	-
Shows TFEB-mediated endocytosis can mitigate amylo…	Supporting	MECH	Exp Neurol	-	2026	0.33	PMID:41506439	-
Explores organelle dysfunction and aggregate sprea…	Supporting	MECH	Physiology (Bet…	-	2026	0.33	PMID:41543365	-
Examines strategies for restoring autophagic flux …	Supporting	MECH	Molecules	-	2026	0.33	PMID:41900026	-
Highlights lysosomal homeostasis as critical in ne…	Supporting	MECH	J Clin Invest	-	2026	0.33	PMID:41919495	-
Cabozantinib activates TFEB-mediated autophagy to …	Supporting	GENE	In Vitro Cell D…	-	2026	-	PMID:41951909	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 10

TFEB links autophagy to lysosomal biogenesis. MEDIUM

Science · 2011 · PMID:21617040 · Q:0.58

ABSTRACT

Autophagy is a cellular catabolic process that relies on the cooperation of autophagosomes and lysosomes. During starvation, the cell expands both compartments to enhance degradation processes. We found that starvation activates a transcriptional program that controls major steps of the autophagic pathway, including autophagosome formation, autophagosome-lysosome fusion, and substrate degradation. The transcription factor EB (TFEB), a master gene for lysosomal biogenesis, coordinated this progra

Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. MEDIUM

J Cell Biol · 2024 · PMID:39196068 · Q:0.59

ABSTRACT

The transcription factor TFEB is a major regulator of lysosomal biogenesis and autophagy. There is growing evidence that posttranslational modifications play a crucial role in regulating TFEB activity. Here, we show that lactate molecules can covalently modify TFEB, leading to its lactylation and stabilization. Mechanically, lactylation at K91 prevents TFEB from interacting with E3 ubiquitin ligase WWP2, thereby inhibiting TFEB ubiquitination and proteasome degradation, resulting in increased TF

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clear… MEDIUM▼

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance.

Immunity · 2025 · PMID:39689715 · Q:0.33

ABSTRACT

Induction of autophagy is an ancient function of the cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway through which autophagic cargoes are delivered to lysosomes for degradation. However, whether lysosome function is also modulated by the cGAS-STING pathway remains unknown. Here, we discovered that the cGAS-STING pathway upregulated lysosomal activity by stimulating lysosome biogenesis independently of the downstream protein kinase TANK-binding kinase 1 (TBK1

TFEB at a glance. MEDIUM

J Cell Sci · 2016 · PMID:27252382 · Q:0.59

ABSTRACT

The transcription factor EB (TFEB) plays a pivotal role in the regulation of basic cellular processes, such as lysosomal biogenesis and autophagy. The subcellular localization and activity of TFEB are regulated by mechanistic target of rapamycin (mTOR)-mediated phosphorylation, which occurs at the lysosomal surface. Phosphorylated TFEB is retained in the cytoplasm, whereas dephosphorylated TFEB translocates to the nucleus to induce the transcription of target genes. Thus, a lysosome-to-nucleus s

Demonstrates enhanced lysosomal activity can prevent protein aggregation and prion seeding, directly supportin…▼

Demonstrates enhanced lysosomal activity can prevent protein aggregation and prion seeding, directly supporting the mitochondrial-lysosomal coupling hypothesis.

J Biol Chem · 2026 · PMID:41391758 · Q:0.49

Shows TFEB-mediated endocytosis can mitigate amyloid pathology, supporting the role of TFEB in cellular qualit…▼

Shows TFEB-mediated endocytosis can mitigate amyloid pathology, supporting the role of TFEB in cellular quality control.

Exp Neurol · 2026 · PMID:41506439 · Q:0.33

Explores organelle dysfunction and aggregate spreading in neurodegeneration, aligning with the proposed mechan…▼

Explores organelle dysfunction and aggregate spreading in neurodegeneration, aligning with the proposed mechanism.

Physiology (Bethesda) · 2026 · PMID:41543365 · Q:0.33

Examines strategies for restoring autophagic flux in protein aggregation diseases, supporting the cellular qua…▼

Examines strategies for restoring autophagic flux in protein aggregation diseases, supporting the cellular quality control perspective.

Molecules · 2026 · PMID:41900026 · Q:0.33

Highlights lysosomal homeostasis as critical in neurodegeneration, directly supporting the hypothesis.

J Clin Invest · 2026 · PMID:41919495 · Q:0.33

Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma.

In Vitro Cell Dev Biol Anim · 2026 · PMID:41951909

✗ Opposing Evidence 3

Acetylation in the regulation of autophagy. MEDIUM

Autophagy · 2023 · PMID:35435793 · Q:0.49

ABSTRACT

Post-translational modifications, such as phosphorylation, ubiquitination and acetylation, play crucial roles in the regulation of autophagy. Acetylation has emerged as an important regulatory mechanism for autophagy. Acetylation regulates autophagy initiation and autophagosome formation by targeting core components of the ULK1 complex, the BECN1-PIK3C3 complex, and the LC3 lipidation system. Recent studies have shown that acetylation occurs on the key proteins participating in autophagic cargo

The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective. MEDIUM

Trends Neurosci · 2016 · PMID:26968346 · Q:0.46

ABSTRACT

The autophagy-lysosomal pathway (ALP) is involved in the degradation of long-lived proteins. Deficits in the ALP result in protein aggregation, the generation of toxic protein species, and accumulation of dysfunctional organelles, which are hallmarks of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and prion disease. Decades of research have therefore focused on enhancing the ALP in neurodegenerative diseases. More recently, transcription factor EB (TFEB), a majo

Mitochondrial-lysosomal contact sites serve multiple functions; disrupting coupling to rescue one pathway may … MEDIUM▼

Mitochondrial-lysosomal contact sites serve multiple functions; disrupting coupling to rescue one pathway may impair others

Nature · 2018 · PMID:30135581 · Q:0.60

ABSTRACT

Barrier tissue dysfunction is a fundamental feature of chronic human inflammatory diseases1. Specialized subsets of epithelial cells-including secretory and ciliated cells-differentiate from basal stem cells to collectively protect the upper airway2-4. Allergic inflammation can develop from persistent activation5 of type 2 immunity6 in the upper airway, resulting in chronic rhinosinusitis, which ranges in severity from rhinitis to severe nasal polyps7. Basal cell hyperplasia is a hallmark of sev

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-02 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Hypotheses: Metabolic Reprogramming in Neurodegeneration

Hypothesis 1: The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction

Title: Impaired TFEB-mediated metabolic coupling between mitochondria and lysosomes drives neuronal death through defective protein aggregate clearance

Mechanism: In neurodegeneration, metabolic stress disrupts the TFEB (Transcription Factor EB) signaling cascade, which normally coordinates mitochondrial biogenesis with lysosomal function. This uncoupling prevents neurons from adequately clearing misfolded proteins while simultaneously reducing

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Rigorous Critique: Fundamental Flaws in Metabolic Neurodegeneration Hypotheses

I'll dissect each hypothesis with the precision of a forensic pathologist examining questionable evidence.

Hypothesis 1: TFEB Mitochondrial-Lysosomal Coupling

Critical Weaknesses:

Correlation ≠ Causation Fallacy: TFEB dysfunction could be consequence, not cause of neurodegeneration
Mechanistic Hand-Waving: "Toxic feedback loop" is descriptive, not explanatory. What are the molecular kinetics?
Oversimplified Binary Logic: Assumes TFEB either works or doesn't, ignoring dose-

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Expert Analysis: Metabolic Reprogramming in Neurodegeneration

Core Metabolic Disruptions in Neurodegeneration

The hypotheses touch on real phenomena, but let me provide the established mechanistic framework:

Glucose Hypometabolism Cascade:

Primary defect: Reduced glucose uptake (GLUT1/GLUT3 dysfunction) precedes neuronal death
Secondary effects: Impaired glycolysis → reduced pyruvate → compromised TCA cycle
Tertiary consequences: Decreased NADPH production → oxidative stress → protein aggregation

Brain Insulin Resistance Mechanism:

**IRS-1/2 serine ph

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 1.3%

Volatility

Low

0.0129

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.436	▲ 3.1%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.423	▲ 6.2%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.398	▼ 1.4%		2026-04-10 15:58
⚖	Recalibrated	$0.404	▲ 1.6%		2026-04-10 15:53
⚖	Recalibrated	$0.397	▲ 0.3%		2026-04-08 18:39
⚖	Recalibrated	$0.396	▼ 0.8%		2026-04-04 16:38
⚖	Recalibrated	$0.399	▼ 3.4%		2026-04-04 16:02
📄	New Evidence	$0.414	▲ 3.9%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.398	▼ 20.4%		2026-04-03 23:46
💬	Debate Round	$0.500	▲ 11.3%	market_dynamics	2026-04-03 08:32
📄	New Evidence	$0.449	▲ 144.6%	market_dynamics	2026-04-03 08:10
📊	Score Update	$0.184	▼ 32.3%	market_dynamics	2026-04-03 05:21
📄	New Evidence	$0.271	▼ 60.8%	market_dynamics	2026-04-03 03:58
📄	New Evidence	$0.692	▲ 1.5%	evidence_batch_update	2026-04-03 01:06
📄	New Evidence	$0.681	▲ 1.8%	evidence_batch_update	2026-04-03 01:06

Clinical Trials (9) Relevance: 34%

0
Active

0
Completed

840
Total Enrolled

PHASE2
Highest Phase

Colchicine for Amyotrophic Lateral Sclerosis PHASE2

COMPLETED · NCT03693781 · Azienda Ospedaliero-Universitaria di Modena

54 enrolled · 2019-04-10 · → 2022-04-14

The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005 mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients. Disease progression as defined

Amyotrophic Lateral Sclerosis

Colchicine 1 MG Oral Tablet Colchicine 1 MG Oral Tablet Placebo Oral Tablet

The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals NA

COMPLETED · NCT03326648 · Truls Raastad

34 enrolled · 2016-09-01 · → 2017-12-20

The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors a

Sarcopenia

Strength training Protein supplementation

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity NA

RECRUITING · NCT06335771 · Bettina Mittendorfer

60 enrolled · 2024-08-01 · → 2028-03

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The

Obesity Nonalcoholic Fatty Liver Diabetes Type 2

Dietary consultation weight loss intervention

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) Unknown

RECRUITING · NCT06571474 · Bettina Mittendorfer

60 enrolled · 2024-08-01 · → 2028-03

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The

Obesity Non-Alcoholic Fatty Liver Disease Diabetes Mellitus, Type 2

Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease NA

NOT_YET_RECRUITING · NCT07337226 · Fondazione Policlinico Universitario Campus Bio-Medico

60 enrolled · 2026-01 · → 2027-10

The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) can improve gait and brain function in people with diagnosis of idiopathic Parkinson's disease (

Idiopathic Parkinson's Disease (PD)

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS) Conventional Physical Therapy (cPT)

The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. NA

ACTIVE_NOT_RECRUITING · NCT04562831 · Haukeland University Hospital

380 enrolled · 2020-10-07 · → 2026-10-31

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effecti

Amyotrophic Lateral Sclerosis

EH301 (Nicotinamide Riboside/Pterostilbene)

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) PHASE2

UNKNOWN · NCT00907283 · Ente Ospedaliero Ospedali Galliera

20 enrolled · 2008-11 · → 2024-12

This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the effica

Neurodegenerative Disease Iron Overload

Deferiprone

Effect of the Vojta Therapy in Patients Multiple Sclerosis NA

UNKNOWN · NCT05558683 · Aymara Abreu Corrales

25 enrolled · 2022-12-01 · → 2023-06-01

Multiple sclerosis is the most common disabling neurological disease in young adults. Inflammation, demyelination, neurodegeneration, gliosis and repair processes are involved in its process, which ar

Multiple Sclerosis

Randomized clinical trial.

The Effect of RNS60 on ALS Biomarkers PHASE2

COMPLETED · NCT03456882 · Mario Negri Institute for Pharmacological Research

147 enrolled · 2017-05-30 · → 2020-11-23

Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatment

Amyotrophic Lateral Sclerosis

RNS60

📚 Cited Papers (40)

TFEB links autophagy to lysosomal biogenesis.

Science (New York, N.Y.) (2011) · PMID:21617040

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy.

Molecules (Basel, Switzerland) (2026) · PMID:41900026

3 figures

Figure 1

The vicious cycle of TDP-43-mediated proteostatic collapse. TDP-43 aggregates actively contribute to pathology rather than merely serving as passive metabolic waste. They sequester...

pmc_api

Figure 2

Nested metabolic hierarchy of therapeutic interventions of TDP-43 proteinopathy. The schematic illustrates the transition from broad metabolic regulation to more precise targeting....

pmc_api

Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.

Scientific reports (2021) · PMID:34285270

8 figures

Figure 1

Minimum inhibitory concentration of vancomycin and teicoplanin for vancomycin-resistant Enterococcus faecium isolates during the outbreak. According to the criteria of the Clinic...

pmc_api

Figure 2

Dendrogram of pulsotypes in pulsed-field gel electrophoresis and sequence types in multilocus sequence typing among vancomycin-resistant Enterococcus faecium isolates (n = 153). ...

pmc_api

Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma.

In Vitro Cell Dev Biol Anim (2026) · PMID:41951909

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Lysosomal homeostasis at the crossroads of neurodegeneration.

The Journal of clinical investigation (2026) · PMID:41919495

3 figures

Figure 1

Mechanisms of lysosomal membrane repair. ( A ) The ESCRT machinery, recruited by galectin-3 (Gal3) and ALIX, polymerizes at rupture sites to reseal small pores. ( B ) The PI4K2A/OR...

pmc_api

Figure 2

Autophagy and lysophagy pathways. Schematic overview of canonical autophagy and selective lysophagy. Under basal or stress conditions, cytoplasmic material, damaged organelles, and...

pmc_api

The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective.

Trends in neurosciences (2016) · PMID:26968346

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Autophagy and ALS: mechanistic insights and therapeutic implications.

Autophagy (2022) · PMID:34057020

3 figures

Figure 1.

Dysfunction of autophagy-related proteins impairs proteostasis and leads to neurotoxicity in ALS. ( A ) Under normal conditions, SQSTM1 serves as a receptor protein in selective au...

pmc_api

Figure 2.

Distinct factors regulate autophagy among different cell types of the nervous system. In each of the cells which comprise the central and peripheral nervous systems, autophagy is d...

pmc_api

Acetylation in the regulation of autophagy.

Autophagy (2023) · PMID:35435793

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

The Lysosome as a Regulatory Hub.

Annual review of cell and developmental biology (2016) · PMID:27501449

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

High resolution spatiotemporal patterns of seawater temperatures across the Belize Mesoamerican Barrier Reef.

Scientific data (2020) · PMID:33199700

3 figures

Fig. 1

Map of logger deployment sites in Belize.

pmc_api

Fig. 2

Cross-sectional view of Carrie Bow Caye describing back reef and the two fore reefs in this area: inner fore reef and outer fore reef.

pmc_api

Organelle dysfunction and TNT-mediated aggregate spreading in neurodegeneration.

Physiology (Bethesda, Md.) (2026) · PMID:41543365

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.

Autophagy (2019) · PMID:30335591

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

📙 Related Wiki Pages (15)

MET Protein protein MET - MET Proto-Oncogene, Receptor Tyrosine Kinase gene TFEB gene TFEB Protein (Transcription Factor EB) protein Neurodegeneration disease TFEB Signaling in Neurodegeneration mechanism TFEB Activators for Parkinson's Disease mechanism TFEB gene Metabolic-Energetic Restoration: GLP-1 + TFEB Acti idea PD TFEB Activator and Lysosomal Biogenesis Compani company Alibaba Tongyi Qianwen-Bio (Chinese Biomedical LLM ai_tool TFEB-Mediated Lysosomal Biogenesis mechanism TFEB (Redirect) redirect TFEB Autophagy Pathway mechanism Mitophagy Gate Therapy: PINK1/Parkin + TFEB Primin idea

࢐ Browse all wiki pages

📓 Linked Notebooks (6)

📓 Metabolic reprogramming in neurodegenerative disease — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-02-gap-v2-5d0e3052. How does metabolic reprogramming (glucose metabolism shifts, brain insulin resistance, ketone body utilization) affect neuronal …

📓 Top 5 Analysis: Sda 2026 04 02 Gap V2 5D0E3052

Computational notebook for SDA-2026-04-02-gap-v2-5d0e3052

📓 SciDEX Analysis: 2026 04 02 Gap V2 5D0E3052

Computational notebook for SDA-2026-04-02-gap-v2-5d0e3052

📓 Metabolic reprogramming in neurodegenerative disease — Executed Analysis Notebook

Rich Jupyter notebook with gene expression heatmap, volcano plot, pathway enrichment, statistical tests, and hypothesis radar chart.

📓 Metabolic reprogramming in neurodegenerative disease - Rich Analysis Notebook

FDG-PET glucose metabolism analysis, metabolic gene expression profiling, therapeutic intervention modeling (ketogenic diet, GLP-1 agonists, metformin).

📓 Metabolic reprogramming in neurodegenerative disease

Analysis ID: SDA-2026-04-02-gap-v2-5d0e3052 Date: 2026-04-02 Domain: neurodegeneration Hypotheses Generated: 3 Knowledge Graph Edges: 31

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.73

47.9th percentile (747 hypotheses)

Tokens Used

5,739

KG Edges Generated

2,890

Citations Produced

Cost Ratios

Cost per KG Edge

191.30 tokens

Lower is better (baseline: 2000)

Cost per Citation

441.46 tokens

Lower is better (baseline: 1000)

Cost per Score Point

10549.63 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.073

10% weight of efficiency score

Adjusted Composite

0.725

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.413	0.510

Wiki Pages

MET Proteinprotein MET - MET Proto-Oncogene, Receptor Tyrosine Kinasegene TFEBgene TFEB Protein (Transcription Factor EB)protein Neurodegenerationdisease TFEB Signaling in Neurodegenerationmechanism TFEB Activators for Parkinson's Diseasemechanism TFEBgene Metabolic-Energetic Restoration: GLP-1 + TFEB Actiidea PD TFEB Activator and Lysosomal Biogenesis Companicompany Alibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_tool TFEB-Mediated Lysosomal Biogenesismechanism TFEB (Redirect)redirect TFEB Autophagy Pathwaymechanism Mitophagy Gate Therapy: PINK1/Parkin + TFEB Priminidea

KG Entities (11)

AMPK C3 CLOCK GFAP GLUT3 GLUT4 HMGCS2 NAMPT PRKAA1 TFEB neurodegeneration

Dependency Graph (1 upstream, 2 downstream)

Depends On

TFEB-PGC1α Mitochondrial-Lysosomal Decouplingrefines (0.5)

Depended On By

Cell-Type Specific TFEB Modulationrefines (0.5)Temporal TFEB Modulation Therapyrefines (0.5)

Linked Experiments (8)

Related Hypotheses

Cell-Type Specific TFEB Modulation

Score: 0.677 | neurodegeneration

Radiation drives pericyte senescence through lysosome acidification failure and stalled late-stage autophagy

Score: 0.652 | neurodegeneration

TFEB-PGC1α Mitochondrial-Lysosomal Decoupling

Score: 0.622 | neurodegeneration

Temporal TFEB Modulation Therapy

Score: 0.609 | neurodegeneration

TFEB Activation Clears Tau-Loaded Endolysosomal Compartments, Preventing Release for Transcellular Spreading

Score: 0.560 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

2.0 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF we pharmacologically activate TFEB (via chronic rapamycin administration at 10mg/kg i.p. for 8 weeks) in the 5xFAD mouse model of Alzheimer's disease THEN we will observe a statistically significant reduction in amyloid-beta 40/42 plaque area (≥30% decrease) and improved performance on spatial memory tasks (Barnes maze latency reduction ≥25%) compared to vehicle-treated 5xFAD mice.

pending conf: 0.65

Expected outcome: A ≥30% reduction in cortical and hippocampal amyloid-beta plaque burden combined with ≥25% improvement in Barnes maze latency to target, both measured after 8 weeks of rapamycin treatment.

Falsified by: No statistically significant reduction in amyloid-beta plaque area (p>0.05) AND no improvement in spatial memory performance (p>0.05) after TFEB activation despite confirmed nuclear TFEB translocation and increased LAMP1/CD68 immunoreactivity.

Method: Randomized controlled experiment in 5xFAD transgenic mice (n=20/group), with rapamycin (10mg/kg, i.p., daily) vs. vehicle control (DMSO/PBS) from 6-9 months of age. Outcome assessment via ELISA of brain amyloid-beta 40/42, stereological plaque quantification, and Barnes maze behavioral testing at weeks 0, 4, and 8.

IF we measure TFEB nuclear localization and CLEAR network gene expression (CTSD, ATP6V1A, GAA) in postmortem prefrontal cortex tissue from matched cohorts of Alzheimer's disease patients (n=30, Braak III-VI) vs. cognitively normal controls (n=30) THEN we will observe significantly decreased nuclear TFEB protein (≥40% reduction) and reduced expression of CLEAR network target genes (≥30% decrease) in AD brains.

pending conf: 0.55

Expected outcome: ≥40% reduction in nuclear TFEB protein levels and ≥30% downregulation of at least 3 CLEAR network genes (CTSD, ATP6V1A, LAMP1) in AD prefrontal cortex tissue compared to age-matched controls.

Falsified by: No significant difference in nuclear TFEB levels between AD and control brains (p>0.05) OR no correlation between TFEB nuclear localization and CLEAR network gene expression (r<0.3, p>0.05), indicating TFEB dysfunction is not a common feature of AD.

Method: Case-control study using postmortem prefrontal cortex tissue from the Accelerating Medicines Partnership Alzheimer's Disease cohort, with nuclear/cytoplasmic fractionation and immunoblotting for TFEB, RT-qPCR for CLEAR network genes (CTSD, ATP6V1A, GAA, LAMP1), and histopathological confirmation of amyloid/tau pathology.

Knowledge Subgraph (28 edges)

associated with (2)

GLUT3→neurodegenerationHMGCS2→neurodegeneration

co discussed (24)

NAMPT→CLOCKNAMPT→PRKAA1TFEB→PRKAA1TFEB→NAMPTPRKAA1→NAMPT

▸ Show 19 more

CLOCK→NAMPTNAMPT→TFEBPRKAA1→TFEBGLUT3→HMGCS2GLUT3→TFEBGLUT3→PRKAA1GLUT3→NAMPTGLUT3→CLOCKHMGCS2→TFEBHMGCS2→PRKAA1HMGCS2→NAMPTHMGCS2→CLOCKGLUT3→GLUT4HMGCS2→GLUT4TFEB→GLUT4HMGCS2→GLUT3GLUT4→TFEBAMPK→C3AMPK→GFAP

interacts with (2)

GLUT3→GLUT4GLUT4→GLUT3

Mechanism Pathway for TFEB

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    TFEB["TFEB"] -->|co discussed| PRKAA1["PRKAA1"]
    TFEB_1["TFEB"] -->|co discussed| NAMPT["NAMPT"]
    NAMPT_2["NAMPT"] -->|co discussed| TFEB_3["TFEB"]
    PRKAA1_4["PRKAA1"] -->|co discussed| TFEB_5["TFEB"]
    GLUT3["GLUT3"] -->|co discussed| TFEB_6["TFEB"]
    HMGCS2["HMGCS2"] -->|co discussed| TFEB_7["TFEB"]
    TFEB_8["TFEB"] -->|co discussed| GLUT4["GLUT4"]
    GLUT4_9["GLUT4"] -->|co discussed| TFEB_10["TFEB"]
    style TFEB fill:#ce93d8,stroke:#333,color:#000
    style PRKAA1 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_1 fill:#ce93d8,stroke:#333,color:#000
    style NAMPT fill:#ce93d8,stroke:#333,color:#000
    style NAMPT_2 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_3 fill:#ce93d8,stroke:#333,color:#000
    style PRKAA1_4 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_5 fill:#ce93d8,stroke:#333,color:#000
    style GLUT3 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_6 fill:#ce93d8,stroke:#333,color:#000
    style HMGCS2 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_7 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_8 fill:#ce93d8,stroke:#333,color:#000
    style GLUT4 fill:#ce93d8,stroke:#333,color:#000
    style GLUT4_9 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_10 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 TFEB — PDB 4NTI Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Metabolic reprogramming in neurodegenerative disease

neurodegeneration | 2026-04-02 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

The Glial Ketone Metabolic Shunt Hypothesis

Score: 0.61 · HMGCS2

Brain Insulin Resistance with Glucose Transporter Dysfunction

Score: 0.60 · GLUT3/GLUT4

→ View all analysis hypotheses

The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

3D Protein Structure (AlphaFold)

Dimension Scores

✓ Supporting Evidence 10

✗ Opposing Evidence 3

Novel Hypotheses: Metabolic Reprogramming in Neurodegeneration

Hypothesis 1: The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction

Rigorous Critique: Fundamental Flaws in Metabolic Neurodegeneration Hypotheses

Hypothesis 1: TFEB Mitochondrial-Lysosomal Coupling

Critical Weaknesses:

Expert Analysis: Metabolic Reprogramming in Neurodegeneration

Core Metabolic Disruptions in Neurodegeneration

Price History

Clinical Trials (9) Relevance: 34%

📚 Cited Papers (40)

📙 Related Wiki Pages (15)

📓 Linked Notebooks (6)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (2)

🧬 Same Target Gene / Disease (6)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

Wiki Pages

KG Entities (11)

Dependency Graph (1 upstream, 2 downstream)

Linked Experiments (8)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (28 edges)

associated with (2)

co discussed (24)

interacts with (2)

Mechanism Pathway for TFEB

3D Protein Structure

Source Analysis

Metabolic reprogramming in neurodegenerative disease

Community Feedback

Same Analysis (2)